- Home
- MEIP vs USEA Comparison
MEIP vs USEA Comparison
Compare MEIP & USEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- USEA
- Stock Information
- Founded
- MEIP 2000
- USEA 2004
- Country
- MEIP United States
- USEA Greece
- Employees
- MEIP 28
- USEA N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- USEA Marine Transportation
- Sector
- MEIP Health Care
- USEA Consumer Discretionary
- Exchange
- MEIP Nasdaq
- USEA Nasdaq
- Market Cap
- MEIP 17.3M
- USEA 16.1M
- IPO Year
- MEIP 2003
- USEA N/A
- Fundamental
- Price
- MEIP $2.60
- USEA $1.85
- Analyst Decision
- MEIP Hold
- USEA Strong Buy
- Analyst Count
- MEIP 2
- USEA 1
- Target Price
- MEIP $7.00
- USEA $6.00
- AVG Volume (30 Days)
- MEIP 7.5K
- USEA 23.8K
- Earning Date
- MEIP 02-12-2025
- USEA 03-04-2025
- Dividend Yield
- MEIP N/A
- USEA 16.22%
- EPS Growth
- MEIP N/A
- USEA N/A
- EPS
- MEIP N/A
- USEA N/A
- Revenue
- MEIP N/A
- USEA $46,160,000.00
- Revenue This Year
- MEIP N/A
- USEA $27.55
- Revenue Next Year
- MEIP N/A
- USEA $5.76
- P/E Ratio
- MEIP N/A
- USEA N/A
- Revenue Growth
- MEIP 33.76
- USEA 11.18
- 52 Week Low
- MEIP $2.30
- USEA $1.63
- 52 Week High
- MEIP $4.42
- USEA $3.00
- Technical
- Relative Strength Index (RSI)
- MEIP 37.79
- USEA 50.46
- Support Level
- MEIP $2.55
- USEA $1.85
- Resistance Level
- MEIP $2.79
- USEA $1.92
- Average True Range (ATR)
- MEIP 0.14
- USEA 0.04
- MACD
- MEIP -0.02
- USEA 0.00
- Stochastic Oscillator
- MEIP 14.71
- USEA 50.00
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.